Biosimilars in Focus: Evaluating Their Role Compared to Adalimumab in Clinical Practice

Abstract

Introduction and Purpose:

Adalimumab, a TNF-α inhibitor, is a cornerstone treatment for autoimmune and inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease. Despite its efficacy, the high cost of adalimumab (Humira®) limits accessibility. The emergence of biosimilars offers cost-effective alternatives with comparable efficacy, safety, and immunogenicity. This article reviews the role of adalimumab biosimilars, their clinical equivalence, and potential to address healthcare challenges.

Materials and Methods:

A comprehensive literature review was conducted to evaluate the structural, functional, and clinical parity of adalimumab biosimilars with the reference product. Key studies on pharmacokinetics, efficacy, safety, therapeutic drug monitoring (TDM), and real-world outcomes were analyzed.

Results:
Adalimumab biosimilars demonstrate equivalent pharmacokinetic profiles and clinical efficacy across conditions, with comparable remission rates and safety profiles. Innovations, such as citrate-free formulations and advanced delivery devices, enhance patient adherence. Biosimilars significantly reduce treatment costs, increasing accessibility, especially in resource-constrained settings. Challenges remain in patient acceptance and managing therapy transitions.

Conclusion:
Biosimilars are transformative in addressing the cost barrier of biologic therapies, maintaining therapeutic equivalence to adalimumab while expanding access globally. Enhanced TDM and patient-centered strategies are essential for optimizing outcomes and maximizing their adoption in clinical practice.